Eicosapentaenoic acid (omega-3 fatty acid)

DIETARY_SUPPLEMENT4 trials

Sponsors

University of Pittsburgh, National Science and Technology Council, Taiwan

Conditions

Bipolar DisorderCOVID - 19Coronary Artery DiseaseDepression - Major Depressive DisorderMDDMajor DepressionMajor Depressive Disorder (MDD)Obese Adults

Phase 2

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

CompletedNCT00167310

University of PittsburghBipolar Disorder, Coronary Artery Disease, Major Depression +2

Start: 2005-09-30End: 2015-12-31Updated: 2017-04-10

Unknown Phase

NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status

RecruitingNCT07439744

National Science and Technology Council, TaiwanMDD, Obese Adults

Start: 2025-03-01End: 2027-12-01Target: 50Updated: 2026-02-27

Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice

RecruitingNCT07462013

National Science and Technology Council, TaiwanMajor Depressive Disorder (MDD)

Start: 2025-10-01End: 2028-09-01Target: 120Updated: 2026-06-17

The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms

CompletedNCT07711444

National Science and Technology Council, TaiwanCOVID - 19, Depression - Major Depressive Disorder

Start: 2024-06-01End: 2026-06-01Updated: 2026-07-21